Contact information
Research groups
Colleges
Asger Jakobsen
BMBCh, MRCP, DPhil
Postdoctoral Clinical Research Fellow
Research groups
I studied medical sciences at the University of Cambridge, and qualified in clinical medicine from Oxford Medical School in 2014. I am currently working as a Clinical Research Fellow in the MRC Molecular Haematology Unit supervised by Prof Paresh Vyas and Prof Doug Higgs.
My research focuses on how mutations affecting epigenetic regulators lead to clonal expansion in haematopoietic stem and progenitor cells. Proteins that control DNA methylation, such as DNMT3A and TET2, are important in stem cell differentiation and regulating how genes are expressed. Mutations in these genes are commonly found in blood cells of healthy older people, lead to clonal expansion, and are associated with increased risk of developing acute myeloid leukaemia (AML) and other haematological cancers. Through this work, we hope to gain a better understanding of how AML develops and identify new therapeutic targets to improve treatment for patients with leukaemia.
Key publications
-
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
-
GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells.
Journal article
Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11
Recent publications
-
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
-
Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Journal article
Freeman SD. et al, (2023), Blood
-
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Journal article
Lachowiez CA. et al, (2023), Blood Cancer Discov, 4, 276 - 293
-
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Other
Lachowiez CA. et al, (2023)
-
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Other
Lachowiez CA. et al, (2023)